Studies have shown that the combination of T1 enhancement, T2-FLAIR, DWI and DSC sequences can better predict IDH mutation in low-grade glioma, and the sensitivity, specificity, and AUC values were 0.707, 0.800, and 0.795, respectively [26]. The gene discussed is IDH1; the disease is central nervous system cancer.